Effect of the cannabinoid CB 1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats

British Journal of Pharmacology

Volumn 150, Issue 5, 2007, Pages 559-566

  Croci, T ^a,b   Zarini, E ^a  

^a Sanofi Midy Research Center   (Italy)

^b Centro Ricerche Sanofi Midy SpA   (Italy)

Author keywords

Allodynia; Arthritis; Cannabinoid; Hyperalgesia; Inflammation; Obesity; Pain; Rats; Rimonabant; SR141716

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FREUND ADJUVANT; NITRATE; NITRITE; RIMONABANT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOBESITY AGENT; NITRIC OXIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADJUVANT ARTHRITIS; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HYPERALGESIA; HYPERSENSITIVITY; LEAN BODY WEIGHT; NONHUMAN; OBESITY; PAW EDEMA; PRIORITY JOURNAL; RAT; SCORING SYSTEM; ANIMAL; ARTHRITIS; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; EDEMA; HEAT; INFLAMMATION; JOINT; METABOLISM; PAIN ASSESSMENT; PAIN THRESHOLD; PATHOLOGY; REACTION TIME; TIME; TOUCH;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-OBESITY AGENTS; ARTHRITIS, EXPERIMENTAL; BODY WEIGHT; EDEMA; FEMALE; FREUND'S ADJUVANT; HEAT; HYPERALGESIA; INFLAMMATION; JOINTS; NITRIC OXIDE; OBESITY; PAIN MEASUREMENT; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; REACTION TIME; RECEPTOR, CANNABINOID, CB1; TIME FACTORS; TOUCH;

EID: 33847666405     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707138     Document Type: Article

References (53)

1. Barbato JE, Zuckerbraun BS, Overhaus M, Raman KG, Tzeng E (2005). Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. Am J Physiol Heart Circ Physiol 289: H228-H236.
2. Berg AH, Scherer PE (2005). Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949.
3. Carai MA, Colombo G, Gessa GL (2005). Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77: 2339-2350.
4. Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leishman AJ, Brewer JM et al. (2005). TNF-blocking therapies: an alternative mode of action? Trends Immunol 26: 518-522.
5. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998). Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63: PL113-PL117.
6. 1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116: 52-61.
7. Cravatt BF, Lichtman AH (2004). The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61: 149-160.
8. 1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122.
9. Decaris E, Guingamp C, Chat M, Philippe L, Grillasca JP, Abid A et al. (1999). Evidence for neurogenic transmission inducing degenerative cartilage damage distant from local inflammation. Arthritis Rheum 42: 1951-1960.
10. Després JP, Golay A, Sjöström L, for the Rimonabant in Obesity-Lipids Study Group (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
11. Di Marzo V, Matias I (2005). Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
12. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843.
13. Fantuzzi G (2005). Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115: 911-919.
14. 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
15. Gimeno RE, Klaman LD (2005). Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 5: 122-128.
16. 1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 82: 154-158.
17. Harden RN (2005). Chronic neuropathic pain. Mechanisms, diagnosis, and treatment. Neurologist 11: 111-122.
18. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
19. Hauner H (2005). Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc 64: 163-169.
20. Idanpaan-Heikkila JJ, Guilbaud G (1999). Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behaviou. Pain 79: 281-290.
21. Inglis JJ, Nissim A, Lees DM, Hunt SP, Chernajovsky Y, Kidd BL (2005). The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther 7: R807-R816.
22. 1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19: 1567-1569.
23. 2 receptor agonist activity in the hind paw incision model of postoperative pain. Eur J Pharmacol 527: 172-174.
24. Laurido C, Hernandez A, Constandil L, Pelissier T (2003). Nitric oxide synthase and soluble guanylate cyclase are involved in spinal cord wind-up activity of monoarthritic, but not of normal rats. Neurosci Lett 352: 64-66.
25. Lim G, Sung B, Ji RR, Mao J (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of WIN 55,212-2 on neuropathic pain behaviors in rats. Pain 105: 275-283.
26. MacFarlane BV, Wright A, O'Callaghan J, Benson HA (1997). Chronic neuropathic pain and its control by drugs. Pharmacol Ther 75: 1-19.
27. Mao J, Price DD, Mayer DJ (1995). Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61: 353-364.
28. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C et al. (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180.
29. McDougall JJ, Karimian SM, Ferrell WR (1994). Alteration of substance P-mediated vasodilatation and sympathetic vasoconstriction in the rat knee joint by adjuvant-induced inflammation. Neurosci Lett 174: 127-129.
30. Mehrotra C, Naimi TS, Serdula M, Bolen J, Pearson K (2004). Arthritis, body mass index, and professional advice to lose weight: implications for clinical medicine and public health. Am J Prev Med 27: 16-21.
31. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS et al. (2001). Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 289: 76-79.
32. Naeini RS, Cahill CM, Ribeiro-da-Silva A, Ménard HA, Henry L (2005). Remodelling of spinal nociceptive mechanisms in an animal model of monoarthritis. Eur J Neurosci 22: 2005-2015.
33. 2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O- tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 280: 18488-18497.
34. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F (1995). Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci Lett 199: 83-86.
35. Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M (2006). Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 147: 552-559.
36. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP et al. (2003). Anti-obesity effect of SR 141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345-R353.
37. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C et al. (1995). Biochemical and pharmacological characterisation of SR 141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947.
38. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
39. Schafers M, Geis C, Svensson CI, Luo ZD, Sommer C (2003). Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 17: 791-804.
40. Schaible HG, Del Rosso A, Matucci-Cerinic M (2005). Neurogenic aspects of inflammation. Rheum Dis Clin North Am 31: 77-101.
41. Simiand J, Keane M, Keane PE, Soubrié P (1998). SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179-181.
42. Smith SR, Terminelli C, Denhardt G (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293: 136-150.
43. Sommer C, Kress M (2004). Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361: 184-187.
44. Sommer C, Schafers M, Marziniak M, Toyka KV (2001). Etanercept reduces hyperalgesia in experimental painful neuropathy. J Peripher Nerv Syst 6: 67-72.
45. Tedesco LS, Fuseler J, Grisham M, Wolf R, Roerig SC (2002). Therapeutic administration of nitric oxide synthase inhibitors reverses hyperalgesia but not inflammation in a rat model of polyarthritis. Pain 95: 215-223.
46. Trayhurn P (2005). Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 184: 285-293.
47. Ueda H (2006). Molecularmechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther 109: 57-77.
48. Vachharajani V, Russell JM, Scott KL, Conrad S, Stokes KY, Tallam L et al. (2005). Obesity exacerbates sepsis-induced inflammation and microvascular dysfunction in mouse brain. Microcirculation 12: 183-194.
49. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Maiorino M, Pietra C et al. (2003). Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 306: 804-814.
50. Welch SP, Huffman JW, Lowe J (1998). Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286: 1301-1308.
51. 2-selective agonist, GW405833. Eur J Pharmacol 528: 65-72.
52. Williams RO, Feldmann M, Maini RN (1992). Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788.
53. Zimmermann M (2001). Pathobiology of neuropathic pain. Eur J Pharmacol 429: 23-37.